Publications
The commercial case for investing in ALS
13 November 2025
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive…
Achieving Accelerated Patient Access to Cancer Care in Europe
3 November 2025
OHE developed the Accelerated Patient Access to Cancer Care in Europe (APACE)…
Patient preferences for treatment in relapsed/refractory acute leukemia
23 October 2025
When acute leukemia relapses, treatment decisions can be complex. Patients may…
The value of cell and gene therapies to the UK economy
20 October 2025
Cell and gene therapies (CGTs) are moving rapidly from specialist trials to…
Insights
Reflections from Adrian Towse on decades of HEOR research and impact
11 November 2025
Adrian Towse, Emeritus Director and Visiting Senior Research Fellow at OHE looks…
Turning around the NHS: Reflections on the 2025 OHE Annual Lecture
14 October 2025
In this year's Annual Lecture, Prof Anita Charlesworth takes a closer look at…
OHE’s submission to a parliamentary inquiry on UK drug shortages
6 October 2025
The following is an extract from OHE’s written submission to parliament…
Environmental sustainability in the NHS 10 Year Health Plan: The need for green
29 September 2025
This is the second in a series of blogs about how the proposals in the recently…
Robust analysis, real-world problems
OHE research supports pragmatic solutions and stronger policy decisions
Areas of expertise
OHE’s expertise covers a wide range of topics
Health Technology Assessment (HTA)
The commercial case for investing in ALS
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive neurodegenerative disease with devastating clinical and…
Achieving Accelerated Patient Access to Cancer Care in Europe
OHE developed the Accelerated Patient Access to Cancer Care in Europe (APACE) framework through a structured,…
Drug Development/R&D
The commercial case for investing in ALS
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive neurodegenerative disease with devastating clinical and…
OHE’s submission to a parliamentary inquiry on UK drug shortages
The following is an extract from OHE’s written submission to parliament focused on diversifying suppliers and recognising…
Digital Health
The true cost and burden of frontotemporal dementia: Early insights into a pressing challenge
In recognition of Frontotemporal Dementia Awareness Week, OHE shares ongoing work quantifying the disease burden and…
OHE’s submission for the DHSC’s next 10 years of planning
This Insight summarises the recommendations OHE submitted towards the Department of Health & Social Care’s consultation…
Prevention
Turning around the NHS: Reflections on the 2025 OHE Annual Lecture
In this year's Annual Lecture, Prof Anita Charlesworth takes a closer look at the NHS 10 Year Health Plan, concluding that…
New OHE model estimates COVID-19 could be associated with costs of £7 billion a year in the UK, without annual autumn vaccinations
A newly released report commissioned by Moderna modelled a one-year scenario without annual COVID-19 autumn vaccinations.